^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ANV419

i
Other names: ANV419, humanized NARA 1 antibody, selective interleukin-2 receptor agonist
Associations
Company:
Anaveon
Drug class:
CD25 inhibitor, IL-2βγR agonist
Associations
14d
ANV419-001: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer. (clinicaltrials.gov)
P1, N=55, Completed, Anaveon AG | Recruiting --> Completed | N=80 --> 55 | Trial completion date: Jan 2025 --> Jul 2024
Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 overexpression
|
Yervoy (ipilimumab) • ANV419
3ms
Balancing the Scales: The Dual Role of Interleukins in Bone Metastatic Microenvironments. (PubMed, Int J Mol Sci)
Current treatment strategies, such as the use of denosumab, tocilizumab, and emerging agents like bimekizumab and ANV419, highlight the potential of interleukin-targeted therapies in mitigating bone metastases...While not exhaustive, this overview underscores the critical roles of interleukins in bone metastases and highlights the need for continued research to fully elucidate their complex interactions and therapeutic potential. Addressing these gaps will be essential for advancing our understanding and treatment of bone metastases in cancer patients.
Review • Journal • Metastases
|
IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL10 (Interleukin 10) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
|
Prolia (denosumab) • Actemra IV (tocilizumab) • ANV419
4ms
Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy. (PubMed, MAbs)
ANV419 also enhances the NK cell killing capacity and increases tumor growth inhibition when used alongside trastuzumab in a Her-2+ xenograft mouse model...These data support the clinical development of ANV419 in solid tumors and hematological malignancies as monotherapy and in combination with checkpoint inhibitors or agents that induce antibody-dependent cellular cytotoxicity. ANV419 is currently in Phase 1/2 clinical development and may provide cancer patients with a wider therapeutic window than aldesleukin.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2 (Interleukin 2)
|
Herceptin (trastuzumab) • Proleukin (aldesleukin) • ANV419
7ms
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. (PubMed, J Immunother Cancer)
In a separate clinical cohort, we retrospectively measured the residual concentration of nivolumab and pembrolizumab, revealing persistent serum concentrations of anti-PD-1/PD-L1 antibodies even months after treatment cessation. This underscores the importance of comprehensively documenting prior immunotherapy details in clinical trials. Such information is crucial for understanding potential interactions that may impact both immunological and clinical effects.
P1 data • Clinical Trial,Phase I • Journal • Metastases
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • ANV419
9ms
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). (clinicaltrials.gov)
P1/2, N=130, Recruiting, Anaveon AG | Trial primary completion date: Jun 2024 --> Sep 2024
Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF V600 • BRAF wild-type
|
Keytruda (pembrolizumab) • Yervoy (ipilimumab) • ANV419
10ms
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. (PubMed, J Immunother Cancer)
ANV419 at doses up to 243 µg/kg (the RP2D) was well tolerated and showed signs of antitumor activity in a heavily pretreated patient population with advanced solid tumors.
P1 data • Clinical Trial,Phase I • Journal • Metastases
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
|
ANV419
over1year
ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors (ESMO 2023)
Preliminary anti-tumor activity was observed including durable response in NSCLC. Further studies assessing the antitumor activity of ANV419 in melanoma and myeloma are ongoing.
Clinical • Metastases
|
CD8 (cluster of differentiation 8)
|
ANV419
over1year
BaseTIL-03M: ACT-TIL and ANV419 for Advanced Melanoma. (clinicaltrials.gov)
P1, N=10, Recruiting, University Hospital, Basel, Switzerland | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
ANV419
over1year
Enrollment change • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 overexpression
|
Yervoy (ipilimumab) • ANV419
over1year
BaseTIL-03M: ACT-TIL and ANV419 for Advanced Melanoma. (clinicaltrials.gov)
P1, N=10, Not yet recruiting, University Hospital, Basel, Switzerland
New P1 trial • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
ANV419
over1year
OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma. (ASCO 2023)
Recombinant IL-2 (proleukin) induces durable responses in approximately 10% of patients with melanoma...In Part 3, the efficacy and safety of ANV419 in combination with the approved doses pembrolizumab or ipilimumab will be evaluated using a Simon’s 2-stage design...Preliminary monotherapy efficacy data are expected by Q1/2024. Clinical trial information: NCT05578872.
Clinical • P1/2 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha)
|
BRAF mutation
|
Keytruda (pembrolizumab) • Yervoy (ipilimumab) • Proleukin (aldesleukin) • ANV419
over1year
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma. (ASCO 2023)
The OMNIA-2 study (ANV419-102; NCT 05641324) will evaluate safety and preliminary efficacy of ANV419 as monotherapy and in combination with daratumumab (dara), or lenalidomide with low dose dexamethasone (lena/dex), in patients with relapsed or refractory multiple myeloma...OMNIA-2 is being conducted in Denmark, France, Germany, Spain, Switzerland, UK and enrolment began in January 2023 and preliminary data are expected in Q1 2024. Clinical trial information: NCT05641324.
Clinical • P1/2 data
|
CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha)
|
lenalidomide • Darzalex (daratumumab) • dexamethasone • ANV419
almost2years
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). (clinicaltrials.gov)
P1/2, N=130, Recruiting, Anaveon AG | Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2024 --> Jun 2024
Enrollment open • Trial primary completion date • Combination therapy • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • Yervoy (ipilimumab) • ANV419
2years
New P1/2 trial • Combination therapy • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Keytruda (pembrolizumab) • Yervoy (ipilimumab) • ANV419
2years
ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein showing increased efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity (SITC 2022)
NK cell killing was analyzed in combination with trastuzumab...Treatment of whole blood with a combination of ANV419 and pembrolizumab (anti-PD1) or ipilimumab (anti-CTLA4) induced only slightly increased cytokine secretion compared to ANV419 alone and is therefore considered to have a reasonable safety profile. Conclusions The data presented here further elucidate the in vitro and in vivo effects of ANV419 and support the rationale for clinical development in indications where NK and CD8 T cells are involved in tumor resolution as well as in combination with ADCC inducing treatments or checkpoint inhibitors.
Clinical • Combination therapy • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Yervoy (ipilimumab) • ANV419
over2years
ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein with potent CD8 T cell and NK cell stimulating capacity that shows additive efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity (ESMO 2022)
In vitro combination of ANV419 with the antibody dependent cellular cytotoxicity (ADCC) inducing anti-HER2 antibody trastuzumab showed additive effects in NK cell killing compared to single trastuzumab treatment...To assess the role of ANV419 in indications where T cells are involved in tumor resolution, ANV419 combination with the checkpoint inhibitors anti-PD1 or anti-CTLA4 was tested and showed additive effects in tumor growth retardation in mice bearing H22 tumors compared to single treated mice. Conclusions The data presented here, support the initiation of clinical phase II studies assessing ANV419 treatment in indications in which NK and CD8 T cells are involved in tumor resolution and in combination with ADCC inducing treatments or checkpoint inhibitors.
Clinical • Combination therapy • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IL2 (Interleukin 2) • IL15 (Interleukin 15) • NKG2D (killer cell lectin like receptor K1)
|
IL2 expression
|
Herceptin (trastuzumab) • ANV419
over2years
ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors, a phase I/II study (ESMO 2022)
Conclusions ANV419 shows a favorable and consistent safety profile across doses and selectively induces expansion and proliferation of CD8 T and NK cells, but not Tregs. Updated clinical data including additional dose cohorts, long term PK/PD and histology will be shared at the meeting.
Clinical • P1/2 data
|
CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2)
|
ANV419
over2years
A phase I/II study of ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors. (ASCO 2022)
Overall, ANV419 is well tolerated and selectively induces expansion and proliferation of CD8 T cells and NK cells, but not Tregs up to a dose of at least 48mcg/kg. Updated data will be shared during the meeting.
Clinical • P1/2 data
|
CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha)
|
CD8 positive
|
ANV419
over2years
ANV419, an IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, induces selective effector cell proliferation in patients with progressed cancer (AACR 2022)
ANV419 is very well tolerated and induces a high degree of proliferation in CD8 T cells and NK cells but not Tregs. ANV419-001 will further evaluate the safety and efficacy of ANV419 alone and in combination with other immunotherapy drugs.
Clinical
|
CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule)
|
ANV419
over3years
Clinical • Enrollment open
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
ANV419
over3years
[VIRTUAL] ANV419 is a new generation CD122-biased IL-2/anti-IL-2 antibody fusion protein with potent stimulatory function on immune effector cells in vitro and in vivo (CIMT 2021)
Novel interleukin-2 (IL-2)-based therapeutic modalities with preferential signaling through the IL-2 β/γ receptor (IL-2Rβ/γ) are entering clinical trials and have the potential to substantially increase the therapeutic index of recombinant IL-2 (aldesleukin) for cancer therapy...The combination treatment with anti-HER2 antibody trastuzumab led to an increased anti-tumor activity of the monoclonal antibody in the gastric cancer N87 xenograft model...Aligned to its potent proliferative effect on CD8 and NK cells, ANV419 induces strong anti- tumor responses in various mouse models of cancer. This pre-clinical data and the marked safety window of ANV419 in non-human primates support its translational development as immunotherapeutic agent in oncology.
Preclinical • IO biomarker
|
CD8 (cluster of differentiation 8) • CD22 (CD22 Molecule) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
|
Herceptin (trastuzumab) • Proleukin (aldesleukin) • ANV419
over3years
Clinical • New P1/2 trial
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
ANV419